Trials that use: Logistic regression
New to this method? Read the tutorial →
47 results
- ABCSG-18Independent statistical analysis of ABCSG-18, a randomized phase 3 trial of denosumab in patients with breast cancer receiving aromatase inhibitor therapy, including trial design, fracture, bone mineral density, disease-free survival, bone metastases-free…
- ACTT-2Independent statistical analysis of ACTT-2, the randomized phase 3 trial of remdesivir plus baricitinib versus remdesivir plus placebo in COVID-19, including time-to-recovery, ordinal-scale, and safety analyses.
- AGO-OVAR 12Independent statistical analysis of AGO-OVAR 12 (NCT01015118), a randomized phase 3 trial of nintedanib or placebo with paclitaxel and carboplatin in first-line ovarian cancer, including progression-free survival, overall survival, response, quality of…
- ALIASIndependent statistical analysis of ALIAS, a randomized phase 3 trial of albumin versus saline in acute ischemic stroke, including trial design, endpoints, logistic regression, risk ratios, nonparametric analysis, safety, and interpretation.
- AMBITIONIndependent statistical analysis of the AMBITION phase 3 trial of first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension, including time-to-event analysis, secondary endpoints, statistical methodology, safety, and interpretation.
- ATLANTICIndependent statistical analysis of ATLANTIC (NCT01347580), a randomized phase 4 trial comparing pre-hospital versus in-hospital initiation of ticagrelor in STEMI patients planned for PCI.
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- CALLAIndependent statistical analysis of the CALLA phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer, including trial design, progression-free survival, overall survival, response endpoints, safety, and statistical…
- CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…
- CANTATAComplete statistical analysis of the phase 3 CANTATA trial, including trial design, HbA1c efficacy, secondary metabolic endpoints, ANCOVA, logistic regression, confidence intervals, and statistical interpretation.
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- LUX-Lung 8Independent statistical analysis of LUX-Lung 8, the phase 3 randomized trial of afatinib versus erlotinib in squamous cell lung cancer after at least one prior platinum-based chemotherapy. Includes progression-free survival, overall survival,…
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- ODINIndependent statistical analysis of the ODIN phase 3 trial comparing once-daily versus twice-daily darunavir/ritonavir in early treatment-experienced HIV-1 infected patients, including non-inferiority methodology, logistic regression, ANCOVA, Cox models, confidence intervals, and reported…
- Partners PrEPAn independent statistical analysis of the Partners PrEP phase 3 trial, examining TDF and FTC/TDF for prevention of HIV-1 acquisition in HIV-1 discordant couples, including Cox regression, hazard ratios, safety, longitudinal analyses,…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PROfoundIndependent statistical analysis of the PROfound phase 3 trial of olaparib versus investigators' choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer, including trial design, time-to-event and response…
- RUXCOVIDIndependent statistical analysis of the phase 3 RUXCOVID trial of ruxolitinib versus placebo in patients with COVID-19 associated cytokine storm, including the primary composite endpoint, secondary outcomes, statistical methods, safety, and interpretation.
- SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…
- STEP 1Complete statistical analysis of STEP 1 (NCT03548935), a randomized phase 3 trial of semaglutide 2.4 mg versus placebo in people with overweight or obesity, including its ANCOVA and logistic-regression analyses, effect estimates,…
- STEP 2Complete statistical analysis of STEP 2, the randomized phase 3 trial of semaglutide in people with type 2 diabetes and overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression,…
- STEP 3Complete statistical analysis of STEP 3 (NCT03611582), a phase 3 randomized trial evaluating semaglutide versus placebo for weight reduction in people with overweight or obesity, including endpoint definitions, ANCOVA, MMRM, logistic regression,…
- STEP 5Complete statistical analysis of the STEP 5 phase 3 trial of semaglutide versus placebo in adults with overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression, confidence intervals, and…
- SURMOUNT-3Independent statistical analysis of the phase 3 SURMOUNT-3 trial of tirzepatide in participants with obesity or overweight after a lifestyle weight loss program, including trial design, primary endpoints, reported estimates, statistical methods,…
- SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.
- SURPASS-3Complete statistical analysis of SURPASS-3, a randomized phase 3 trial comparing tirzepatide with insulin degludec in participants with type 2 diabetes, including HbA1c, body weight, fasting serum glucose, treatment satisfaction, statistical methodology,…
- SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.
- SURPASS-5Complete statistical analysis of SURPASS-5, a randomized phase 3 trial of tirzepatide versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin.
- TDF2Independent statistical analysis of the randomized TDF2 trial of tenofovir disoproxil fumarate plus emtricitabine for HIV prevention, including trial design, registered endpoints, Cox and logistic regression methods, reported results, safety, limitations, and…
- THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.